LTIMindtree Partners with Metasphere to Deliver Smart Sewers Solutions

 LONDON & MUMBAI, India - Thursday, 30. November 2023

(BUSINESS WIRE) -- LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced that it has been selected as a strategic partner by Metasphere, a wastewater application specialist, to scale their Smart Sewers management platform. As a part of this engagement, LTIMindtree will transform Metasphere’s next-generation wastewater monitoring solution portfolio, and enable scalable delivery and platform to their customers.

Metasphere, part of Grundfos, provides smart network management solutions to the global utility industry. The company helps customers prevent leaks and spills for a cleaner, greener world and has deployed more than 200K sensors for their customers worldwide. By leveraging cutting-edge technology, the company offers intelligent, innovative, all-in-one wastewater application solutions. These solutions provide full network visibility, performance and forecasting that reduce telemetry ownership cost for customers to manage time-critical remote assets and system.

Sudhir Chaturvedi, President and Executive Board Member, LTIMindtree, said, “We are excited to partner with Metasphere, a Grundfos company, in their modernization program. With increasing focus on utilities worldwide, it has become critical to improve service delivery, reduce accidents and deliver real-time insights to customers. After careful consideration by our team of experts, LTIMindtree took Metasphere's cloud architecture and optimized it for AWS scale and cost. This transformation is enabling Metasphere in optimizing up to 25% of the total cost, while delivering almost unlimited scale and enhanced performance.”

Tim O’Brien, Chief Executive Officer, Metasphere, said, “This engagement is key to our ability to deliver modern, scalable solutions to all our utility clients worldwide. In LTIMindtree, we found an expert partner to support our diverse needs and bring in additional innovative offerings that we can integrate in our system in the future. We are confident that this partnership will bring us closer to our vision of leveraging our solutions to serve at least 10% of world’s population by 2040.”

The modernised solutions designed by LTIMindtree and built on AWS have significantly reduced Metasphere’s customer onboarding time from days to minutes and activated faster rollout of new features.

Paddy Fitzpatrick, UKI ISV Head, AWS, said, “We are excited to see organisations like LTIMindtree deliver innovative solutions for the water industry by building on AWS. This collaboration between LTIMindtree and Metasphere will give the utility industry access to new solutions such as real-time network visibility and wastewater monitoring to help reduce costs and enhance performance. Together, we can help the utility industry leverage the power of cloud to drive business value.”

About LTIMindtree:

LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 83,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.

About Metasphere:

Metasphere is a global industry brand, synonymous with telemetry excellence to help our customers prevent leaks and spills for a cleaner, greener world. As a wastewater application specialist business, we provide monitoring solutions to the global utility industry with installations in more than 25 major utilities, government agencies and system integrators. We liaise with all sectors of the industry, from major utility companies to environmental and regulatory bodies. With operations in the UK and Australia, our friendly expert team is always ready to help with your telemetry and monitoring needs, whether relating to water, wastewater, environment or gas. For more information, please visit https://www.metasphere.co.uk/.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129720313/en/

Permalink
https://www.aetoswire.com/en/news/3011202336222

Contacts

LTIMindtree Media Contact: Shambhavi Revandkar | shambhavi.revandkar@ltimindtree.com
Metasphere Media Contact: Ret Mathieson | ret.mathieson@metasphere.co.uk

 

QPS Holdings, LLC Expands Operations in Springfield, Missouri

 (BUSINESS WIRE) -- QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri. The new facilities include a clinical (safety) laboratory, an updated self-contained pharmacy, and a new dedicated space to build and ship clinical trial kits. The 2,750-square-foot facility is fully operational as of the fall of 2023 and will give QPS significant flexibility in clinical research study operations.

The state-of-the art laboratory is equipped with the most up-to-date technologies for Chemistry, Urinalysis, Serology, Coagulation, and Hematology testing, designed to monitor subject safety during ongoing clinical trials. The updated pharmacy now houses multiple fully certified pharmacists and compounding facilities, and the clinical trial kit facility can pick, pack and ship orders anywhere in the world, usually within 24 hours.

“QPS Missouri continues to expand and offer new services in Springfield, and the addition of a safety lab, the updated pharmacy and the clinical trial kit production area were the next steps to enhance our capabilities to provide comprehensive clinical trial services to the local Springfield community,” stated Brendon Bourg, QPS Missouri Vice President, Early Phase Clinical and Head of Administration. “Adding this new safety lab to our local clinical trial facility means that our physicians can receive laboratory results in real-time, adding an additional level of safety for participants. In addition, QPS can now offer these new clinical trial capabilities to our valued clients.”

Over the next few years, Bourg expects these new facilities to grow from providing services for clinical trials running in the Springfield facility, into providing central laboratory, pharmacy, and clinical trial kit-building services for multi-site clinical research projects, expanding the value of the services provided to all QPS clients.

ABOUT QPS HOLDINGS, LLC

QPS Holdings, LLC, is a global clinical research organization (CRO), that supports the preclinical, bioanalytical, and clinical development of new pharmaceutical products. It is headquartered in Newark, Delaware, and has 7 clinical research and development sites that house a mix of preclinical, bioanalytical, and clinical trials research facilities. These sites are in the USA (Delaware, Florida, and Missouri), The Netherlands, Taiwan, China, and India. To learn more about QPS Holdings, LLC, visit https://www.qps.com.

QPS Missouri is a QPS Holdings, LLC flagship clinical site in Springfield, Missouri, USA. The Springfield campus houses 5 independent clinics with over 240 Phase I clinical trial beds, multiple laboratories, a 2,500 square foot negative pressure room, a pharmacy with a clean room, and a new Screening and Recruitment Center. Since opening its doors in Springfield in 1994, QPS Missouri has conducted over 2,100 FDA-regulated studies and paid out over $35 million to as many as 50,000 local participants. To learn more about QPS Missouri, visit https://www.417studies.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231204471818/en/

Permalink

https://www.aetoswire.com/en/news/0412202336281

Contacts

Trent Chance

417.831.2048

Trent.Chance@qps.com

https:/417studies.com

PUMA RE:SUEDE Pilot Project Turns Experimental Sneakers Into Compost

 HERZOGENAURACH, Germany - Wednesday, 29. November 2023



(BUSINESS WIRE)--Sports company PUMA showed that it can successfully turn an experimental version of its classic SUEDE sneaker into compost under certain tailor-made industrial conditions, as it announced the results of its two-year-long RE:SUEDE experiment.

In 2021, PUMA created 500 pairs of the experimental RE:SUEDE, using Zeology tanned suede, a TPE outsole and hemp fibres. The RE:SUEDEs were worn for half a year by volunteers in Germany to test the comfort and durability of the shoes before PUMA sent them to a specially equipped industrial composting area operated by its partner Ortessa Group in the Netherlands.

A special procedure had to be established to turn the shoes into compost. First, they were shredded and mixed with other green household waste and placed into a composting tunnel. They were then sprayed with leaching-water from earlier composting that contains nutrients and naturally heated due to the biological activity and controlled air circulation in the tunnel. After approximately 3.5 months, the materials that were small enough (<10mm) to pass through a sieve were sold as Grade A compost for agricultural use (within the standards of the Netherlands), while the remaining materials were returned to the composting tunnel until they too had broken down to the desired level (<10mm). Ortessa Group adhered to all legal requirements for compost applicable at their facilities in the Netherlands during this process.

“While the RE:SUEDE could not be processed under the standard operating procedures for industrial composting, the shoes did eventually turn into compost,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We will continue to innovate with our partners to determine the infrastructure and technologies needed to make the process viable for a commercial version of the RE:SUEDE, including a takeback scheme, in 2024.”

Transparency is another important pillar of the RE:SUEDE experiment, as PUMA will share its insights in a detailed report, so its peers and other interested stakeholders can learn from the experiment and apply the learnings to their own initiatives.

“We learned a lot during the RE:SUEDE trial and how to streamline our industrial composting process to include items that need longer to turn into compost,” said Marthien van Eersel Manager Materials & Innovations at Ortessa. “While all RE:SUEDE materials can decompose, the sole of the RE:SUEDE required more pre-processing and additional time in the composting tunnel to completely break down.”

As a result of the feedback received from the people who wore the RE:SUEDE for half a year, PUMA will improve the comfort of future versions of the shoes by enhancing the overall fit by using a new material pattern for the upper and the sock liner.

The RE:SUEDE experiment was the first programme, together with the novel polyester recycling programme RE:FIBRE, to launch as part of PUMA’s “Circular Lab”, an innovation hub led by PUMA’s innovation and design experts with the aim to create the future of the company’s circularity programmes.

For more information, please visit www.Foreverbetter.com and ortessa.com

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

Ortessa Group

Ortessa is a group of five enterprising waste companies: veyzle, Lammertyn.net, van Kaathoven, Rondo and Valor Composting. Together, the subsidiaries master all links of waste management, collection and processing and prove daily the power of smart partnering. Each with its own specialism in the field of waste, but with one clear joint mission: to be open about waste. With a realistic, pragmatic and results-oriented view, the Ortessa Group helps clients deal with waste challenges.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129456533/en/

Permalink
https://www.aetoswire.com/en/news/2911202336166

Contacts

Samantha Du Plessis – PUMA SE – samantha.duplessis@puma.com

M. Schepers – Ortessa – communicatie@ortessa.com

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

 ZUG, Switzerland - Thursday, 30. November 2023

Both trials met their primary endpoints, demonstrating treatment with RelabotulinumtoxinA resulted in a statistically significant improvement in frown lines and crow’s feet.1,2

Results reinforce the rapid onset of action of RelabotulinumtoxinA, with some patients reporting improvement as early as day one in both trials.1,2

Results also underscore the durability of RelabotulinumtoxinA with at least a third of patients rating their frown lines as ‘improved’ or better through to month 12 in one study.2

Treatment was well tolerated and all treatment-related adverse events were reported as non-serious.1,2

 

(BUSINESS WIRE) -- Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet). Both studies met their primary endpoints, demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, significantly improves both frown lines and crow’s feet, with a rapid onset of action as early as day one and long duration.1,2

 

“These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of RelabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 

 

43QM2106 is a phase IIIb, randomized, double-blind, placebo-controlled trial to assess the aesthetic improvement and onset of action of RelabotulinumtoxinA in patients with moderate to severe frown lines. The trial met its primary endpoint, with 92.9% of those treated with RelabotulinumtoxinA rating their frown lines as ‘improved’ or better on the Global Aesthetic Improvement Scale (GAIS) at month one, compared to 9.1% of those treated with placebo (P<0.001).1

Results reinforced the rapid onset of action and durability of RelabotulinumtoxinA, with 40% of patients rating themselves as ‘improved’ or better on the GAIS as early as day one, and more than a third (38%) of patients rating themselves as ‘improved’ or better at month 12. In addition, 68% and 43% of patients rated themselves as ‘improved’ or better at months six and nine respectively, and 40% of patients also reported at least a one grade improvement of frown line severity at month nine. RelabotulinumtoxinA was well tolerated; the majority of patients did not experience any adverse events and there were no related serious adverse events reported.1

43QM2107 is a phase IIIb, open-label, single-center study to assess aesthetic improvement of RelabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines. It also met its primary endpoint, with 100% of patients treated with RelabotulinumtoxinA rating their crow’s feet and frown lines as ‘improved’ or better on the GAIS at month one.2

RelabotulinumtoxinA demonstrated a rapid onset of action for both crow’s feet and frown lines, with the majority of patients (68% and 60% for crow’s feet and frown lines, respectively) rating themselves as ‘improved’ or better on the GAIS starting at day one. By day two, 100% of patients noted improvement for crow’s feet and 96% noted improvement for frown lines. This was reinforced by Subject Live Assessment results using a validated scale, which showed that 40% of patients on day one and 96% of patients on day four received a score of zero or one on a four-point scale for crow’s feet severity at maximum expression. For frown line severity, 32% of patients on day one and 92% of patients on day four received a score of zero or one. RelabotulinumtoxinA was well tolerated, with no adverse events reported in 92% of patients.2

Results from both studies are in line with those previously seen for RelabotulinumtoxinA.3,4

About RelabotulinumtoxinA (QM1114) 

Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain and manufactured using a unique state-of-the-art process. It is designed as a liquid, avoiding the traditional requirement to reconstitute from powder and eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.

About Galderma 

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

Galderma data on file: initial results of the phase IIIb 43QM2106 trial

Galderma data on file: initial results of the phase IIIb 43QM2107 trial

Shridharani, S., et al. Treatment of moderate-to-severe glabellar lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-1 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022

Ibrahim, SF, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-2 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129534821/en/

Permalink

https://aetoswire.com/en/news/3011202336209

Contacts

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Sébastien Cros

Corporate Communications Director

sebastien.cros@galderma.com

+41 79 529 59 85

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Adani Power to Co-fire Green Ammonia at its Mundra Plant for a Sustainable Future

AHMEDABAD, India - Wednesday, 29. November 2023

• Green Ammonia, whose combustion produces no CO2 emission, to co-fire a 330MW Unit
• APL is working with Japan’s IHI Corporation & KOWA for the pilot
• The project is under the aegis of Japan-India Clean Energy Partnership

(BUSINESS WIRE)--As the world leaders converge in the UAE for the UN Climate Change Conference (COP 28) from 30 November to 12 December 2023 to fast-track energy transition and slash emissions before 2030, Adani Power Ltd., India’s largest private sector power generator, has undertaken a ground-breaking green ammonia combustion pilot project at its Mundra plant as part of its multipronged decarbonization initiatives.

As part of the project, the Mundra Plant, which is India’s largest private sector power plant, will co-fire up to 20% green ammonia in the boiler of a conventional coal fired 330MW Unit.

Green ammonia, produced from green hydrogen, which in turn is produced through electrolysis using renewable energy, would be a feedstock for the boilers. As ammonia contains no carbon, there is no CO2 emission from its combustion, making it a long-term carbon neutral alternative to fossil fuels. Adani Power has already set a benchmark in the industry for ‘per-unit’ emissions and has adopted state of the art ‘Ultra Supercritical technology’ in its newest plants.

Adani Power has partnered with Japan’s IHI and Kowa to deliver the pilot and examine expansion to other APL units and stations. Kowa is active in energy saving and energy creating products, while IHI is a heavy industry company which has ammonia firing technology.

Combustion tests at IHI’s facility in Japan have begun with 20% ammonia blend, simulating Mundra Power Station equipment. The partners believe that the results will be encouraging enough to implement this solution at the Mundra Power Station once economic parity is achieved between both feedstocks. The Mundra plant is the first location outside of Japan to have been selected for this cutting-edge green initiative.

The project has been conceived under the aegis of Japan-India Clean Energy Partnership (CEP), which aims to ensure energy security, achieve carbon neutrality, and achieve economic growth. It has been selected under the New Energy and Industrial Technology Development Organization’s (NEDO) "International Demonstration Project for Japanese Technologies Contributing to Decarbonization and Energy Transition". NEDO is Japan’s national research and development agency that fosters innovation by promoting technological development necessary for realization of a sustainable society.

“Adani Power is fully committed to reducing its carbon footprint through adoption of latest technologies and proactive measures across our business value chain. In furtherance of this vision, we are happy to partner with IHI and Kowa for blending green ammonia for our Mundra plant, which will reduce CO2 emissions. We will continue to integrate cutting-edge technologies increasingly to reduce emissions in the intermediate term,” said Mr. Anil Sardana, Managing Director, Adani Power Ltd.

For more information, visit www.adanipower.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129215046/en/

Permalink
https://www.aetoswire.com/en/news/2911202336174

Contacts

For media queries, contact Roy Paul: roy.paul@adani.com

Aviz Networks Expands Funding to $10M With New Investments From Accton, Cisco Investments and Wistron

 SAN JOSE, Calif. 

Funding to accelerate customer momentum for Aviz’s multi-vendor, GenAI-based networking stack along with adoption of SONiC based open networking

(BUSINESS WIRE)--Aviz Networks, a leader in open networking software for cloud-scale infrastructures serving telecom and enterprises, today announced it has added Cisco Investments to its latest funding expansion, joining existing investors, Moment Ventures, Accton and Wistron. This funding round, now reaching $10M, will accelerate customer momentum for Aviz’s multi-vendor, GenAI-based networking stack along with adoption of SONiC based open networking.

Aviz helps organizations achieve the performance and cost benefits of hyperscale networks by removing complexity and supplying AI-driven management features as part of a breakthrough Networking 3.0 software stack. Aviz’s stack supports the fast-growing SONiC open-source network OS (NOS) as well as multi-NOS environments and leverages the power of large-language-models (LLMs) to deliver unparalleled choice and capabilities. The company has seen rapid growth over the past 12 months, scaling its number of customers, revenue, and operational headcount to meet growing demand across multiple geographies. Aviz has witnessed a 250% growth in revenues with over 30 global customer engagements of various size.

Over the past three years, SONiC has emerged as a multibillion entity in the cloud and data center networking space, expected to reach $8B by 2027, according to research from communications industry analyst firm 650 Group.

“We are delighted to close this latest funding round that includes Accton, Cisco Investments, Moment Ventures, and Wistron. Our vision of delivering open, cloud & AI enabled networks for all enterprises and telecoms has rapidly taken shape as we partner with customers and our vendor ecosystem,” said Vishal Shukla, Co-Founder and CEO for Aviz. “Aviz continues to focus on supporting and leveraging community SONiC, and adding compelling innovations that enhance quality, drive down costs and accelerate time to deployment of open, cloud networks.”

“Accton is proud to be participating in this investment round with other global network leaders as it underscores our commitment to innovation in open networking. Aviz Networks has been extremely successful this year in the multi-billion dollar open network market, where SONiC plays a significant role. Accton is always pleased to collaborate with those that share our collective vision of employing AI and other cutting-edge technologies to meet the networking needs of enterprises and telcos,” said Jun Shi, CEO and President of Accton Group.

“Cisco is committed to accelerating innovation in networking to deliver comprehensive solutions to our customers,” says Aleem Rizvon, Vice President of Cisco Investments. “By investing in innovative startups, like Aviz, we are demonstrating our commitment to our partners and customers who value the open-source community.”

“Wistron is excited to see the multiple innovations and execution coming from Aviz as an early-stage company extending its reach to address the challenges of enterprise data center and cloud networks,” said William Lin, President of Enterprise & Networking B.G., Wistron Corporation. “Wistron is participating in this investment round so that our companies can work closely together to deliver the right solutions and substantial cost savings to enterprises as driven with robust SONiC edge deployments.”

About Aviz

Aviz Networks is a leading provider of solutions for Open, Cloud, and AI first networks. Aviz delivers switch platform agnostic, easy-to-use applications and APIs for network observability, orchestration, and assurance. Aviz also provides disaggregated support for multi-vendor SONiC deployments in data centers & edge networks. Aviz is on a mission to make SONiC a ubiquitous, accessible, and intelligent NOS for every stakeholder.

Learn more about Aviz at aviznetworks.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231130443996/en/

Permalink

https://www.aetoswire.com/en/news/20231130443996r1

Contacts

 

Aviz Networks Contact:

vishal@aviznetworks.com

ReValve Solutions Announces Successful First-in-Human with Next Generation TMVR Technology

 IRVINE, Calif. - Wednesday, 29. November 2023 AETOSWire

(BUSINESS WIRE)--ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System.

The next generation TMVR procedure was performed using ReValve’s Palmetto System on October 11, 2023, at the Punta Pacifica Hospital, Panama City, Panama by Interventional Cardiologists Dr. Charles Davidson (Medical Director, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital) and Dr. Temistocles Diaz (Chief of Interventional Cardiology at Punta Pacifica Hospital), along with Cardiovascular Surgeon Dr. Douglas Boyd, (Professor of Surgery, Vice Chair, Department of Cardiovascular Sciences, East Carolina University) and Echocardiographer Dr. Edris Aman (Assistant Clinical Professor of Cardiovascular Medicine at the University of California, Davis Medical Center). The procedure was successfully completed in under an hour reducing the patient’s MR to trace. At 30 days, the patient continues to do well with zero MR and preserved ventricular function.

ReValve’s technology is designed to replace the Mitral Valve while also preserving the heart’s natural basal left ventricular function. “Our approach to TMVR is unique in that we work with the natural movement of the heart, as opposed to first-generation technologies which require the heart to work around a stiff implant. Our flexibility and four-point securement system provide a patent LVOT and maintains left ventricular function throughout recovery,” said Julie Logan Sands, Founder and CEO ReValve Solutions. “Many of the issues of Neo-LVOT and LV dysfunction were not fully understood nor anticipated in first generation technologies. ReValve’s first-of-its-kind TMVR is thoughtfully designed to expand the treatable population of patients suffering from Mitral Valve Disease,” added Sands.

“The procedure is straightforward, while the valve and delivery system performed as designed. Leaflet securement along with the low-profile valve frame helps to avoid LVOT obstruction that has been a significant limitation of several TMVR technologies. This first in human experience is very encouraging to expand transcatheter mitral valve replacement to a larger population,” said Dr. Davidson.

“The ReValve system is a promising technology. The immediate patient recovery is quite remarkable with preservation of the left ventricular function. The next morning the patient stated he was ready to sing again, we could not have had a better outcome,” said Dr. Diaz.

About ReValve Solutions

The Palmetto System is a complete mitral valve replacement system delivered via transfemoral-transseptal approach. The system is designed to avoid any disturbance to the left-ventricular outflow tract while preserving the basal left ventricular function and if needed, will allow for future replacement through a dedicated product line. Preserving options for the physician and patient is an essential part of the long-term solution to structure heart treatment. ReValve is an investigational device only and not available for sale.

ReValve Solutions, Inc. (www.revalvesolutions.com) is based in Irvine, CA with the mission of delivering innovative solutions to structural heart disease through catheter-based procedures which allow for long-term treatment options. For more information visit www.ReValveSolutions.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129287213/en/

Permalink

https://aetoswire.com/en/news/2911202336182

Contacts

Julie Logan Sands, Jsands@revalvesolutions.com